tiprankstipranks
Stevanato Group Spa (DE:87N)
NYSE:87N
Germany Market

Stevanato Group (87N) Earnings Dates, Call Summary & Reports

3 Followers

Earnings Data

Report Date
Aug 11, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.13
Last Year’s EPS
0.11
Same Quarter Last Year
Based on 4 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 07, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlighted strong top-line growth, robust Biopharmaceutical & Diagnostic Solutions momentum (notably syringes, biologics and GLP1 exposure), expanding high-value solution mix, margin expansion on an adjusted basis, and clear progress on strategic capacity investments. Offsetting these positives were a sharp revenue decline in the Engineering segment, segment-level gross margin compression for BDS driven by ramp-related depreciation, FX and tariff headwinds, a higher tax rate, modest free cash flow in the quarter due to heavy growth capex, and slower order conversion cycles in Engineering. Management reiterated full-year guidance and emphasized demand-driven capacity investment and operational optimization.
Company Guidance
Stevanato reiterated its 2026 guidance: revenue EUR 1.260–1.290 billion, adjusted EBITDA EUR 331.8–346.9 million, and adjusted diluted EPS EUR 0.59–0.63 (March assumptions unchanged); management expects high‑value solutions to represent ~47–48% of 2026 revenue, GLP‑1 volumes to grow in the mid‑teens year‑over‑year (GLP‑1s are ~21–22% of current revenue), and BDS gross margin to be in line with or slightly above 2025 despite an estimated ~EUR 18 million FX headwind and higher depreciation. They expect roughly 45% of full‑year revenue in H1 with a stronger H2, Q2 BDS growth of high single‑digit to low double‑digit and about a 10% decline in Engineering (Engineering down mid‑single to low‑double digits for the year), and note continued capital investment (Q1 capex EUR 67.6 million, >90% growth‑related) with cash EUR 111.7 million and net debt EUR 337.7 million to fund the plan.
Top-line Growth
Revenue grew 10% at constant currency and 7% reported to EUR 273.6 million in Q1 FY2026 versus Q1 2025.
BDS Segment Outperformance
Biopharmaceutical and Diagnostic Solutions (BDS) revenue increased 16% at constant currency (13% reported) to EUR 249.0 million, driven by strong demand for pre-fillable syringes and contributions from cartridges and vials.
Syringes and Biologics Momentum
Syringes grew over 20% year-over-year; biologics revenue rose 15% (fastest-growing end market); GLP1s accounted for ~21%–22% of total company revenue in Q1 2026.
Higher Mix of High-Value Solutions
Revenue from high-value solutions increased 17% to EUR 128.6 million and represented 47% of total company revenue (≈52% of BDS segment revenue).
Profitability and Margin Expansion (Adjusted)
Adjusted EBITDA increased 14% to EUR 65.5 million and adjusted EBITDA margin expanded 150 basis points to 23.9%. Adjusted net profit rose 5% to EUR 29.6 million and adjusted diluted EPS increased 10% to EUR 0.11.
Gross and Operating Margin Improvement
Company gross profit margin increased by 30 basis points to 27.5% and operating profit margin rose 70 basis points to 14.2% in Q1 2026.
Operational Progress on Capacity Expansions
Converted an underutilized RTU vial line to a ready-to-use cartridge line (expected commercial production in coming weeks). Latina and Fishers ramps progressing: Fishers device assembly and automation on track (commercial production end-2026/early-2027); RTU 400 EZ-fill cartridge lines targeted for early 2027.
Cash Generation and Investment
Net cash from operating activities was EUR 75.5 million in Q1; capital expenditures totaled EUR 67.6 million ( >90% for growth in Fishers and Latina). Ending cash EUR 111.7 million with maintained guidance for FY2026.
Guidance Reiterated
Company maintained FY2026 guidance: revenue EUR 1.260B–1.290B, adjusted EBITDA EUR 331.8M–346.9M, adjusted diluted EPS EUR 0.59–0.63.
Engineering Segment Margin Recovery Signs
Engineering gross profit margin improved 460 basis points to 15.3% and operating margin improved 190 basis points to 6.6%, reflecting benefits from the optimization plan and right-sizing actions.

Stevanato Group (DE:87N) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DE:87N Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 11, 2026
2026 (Q2)
0.13 / -
0.11
May 07, 2026
2026 (Q1)
0.10 / 0.11
0.110.00% (<+0.01)
Mar 04, 2026
2025 (Q4)
0.17 / 0.18
0.19-5.26% (-0.01)
Nov 06, 2025
2025 (Q3)
0.13 / 0.14
0.1216.67% (+0.02)
Aug 05, 2025
2025 (Q2)
0.10 / 0.11
0.0922.22% (+0.02)
May 08, 2025
2025 (Q1)
0.09 / 0.10
0.0825.00% (+0.02)
Mar 06, 2025
2024 (Q4)
0.18 / 0.19
0.185.56% (+0.01)
Nov 05, 2024
2024 (Q3)
0.13 / 0.12
0.15-20.00% (-0.03)
Aug 06, 2024
2024 (Q2)
0.10 / 0.09
0.14-35.71% (-0.05)
May 09, 2024
2024 (Q1)
0.11 / 0.08
0.11-27.27% (-0.03)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:87N Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 07, 2026
€16.00€15.10-5.63%
Mar 04, 2026
€12.60€14.70+16.67%
Nov 06, 2025
€21.60€21.00-2.78%
Aug 05, 2025
€21.80€20.00-8.26%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Stevanato Group Spa (DE:87N) report earnings?
Stevanato Group Spa (DE:87N) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
    What is Stevanato Group Spa (DE:87N) earnings time?
    Stevanato Group Spa (DE:87N) earnings time is at Aug 11, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Stevanato Group Spa stock?
          The P/E ratio of Stevanato Group is N/A.
            What is DE:87N EPS forecast?
            DE:87N EPS forecast for the fiscal quarter 2026 (Q2) is 0.13.